IPLEDGE program (English Wikipedia)

Layton A (May 2009). "The use of isotretinoin in acne". Dermato-Endocrinology. 1 (3): 162–9. doi:10.4161/derm.1.3.9364. PMC 2835909. PMID 20436884.
Layton AM, Knaggs H, Taylor J, Cunliffe WJ (September 1993). "Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment". The British Journal of Dermatology. 129 (3): 292–6. doi:10.1111/j.1365-2133.1993.tb11849.x. PMID 8286227. S2CID 22251719.
Thiboutot DM, Cockerell CJ (August 2006). "iPLEDGE: A Report from the Front Lines of Dermatologic Practice". The Virtual Mentor. 8 (8): 524–8. doi:10.1001/virtualmentor.2006.8.8.pfor1-0608. PMID 23234692.
Sladden MJ, Harman KE (September 2007). "What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?". Archives of Dermatology. 143 (9): 1187–8. doi:10.1001/archderm.143.9.1187. PMID 17875883.
Shin, Janet; Cheetham, T. Craig; Wong, Linda; Niu, Fang; Kass, Elizabeth; Yoshinaga, Monica A.; Sorel, Mike; McCombs, Jeffrey S.; Sidney, Stephen (December 2011). "The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system". Journal of the American Academy of Dermatology. 65 (6): 1117–1125. doi:10.1016/j.jaad.2010.09.017. PMID 21565419.
Prevost N, English JC (October 2013). "Isotretinoin: update on controversial issues". Journal of Pediatric and Adolescent Gynecology. 26 (5): 290–3. doi:10.1016/j.jpag.2013.05.007. PMID 24147278.
Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, Koren G, Lavigne SV, Martinez LP, Miller RK, Carey JC (November 2005). "A survey of pregnant women using isotretinoin". Birth Defects Research. Part A, Clinical and Molecular Teratology. 73 (11): 881–7. doi:10.1002/bdra.20197. PMID 16228976. Almost 1/4 of the women surveyed (24%; 8/34) did not recall having contraception counselling before starting their medications. Once therapy was initiated, 62% (21/34) recalled using a birth control method, but only 29% (6/21) recalled using 2 forms of birth control, as specified by the voluntary pregnancy prevention programs. Monthly pregnancy tests were not always conducted during treatment, as recalled by the surveyed women (56%; 19/34). As many as 24% (8/34) of the women surveyed recalled that they were not screened using 2 pregnancy tests before receiving a prescription, another recommendation of the programs. Only a small number of the women (30%; 6/20) in the United States recalled being enrolled in any manufacturers' voluntary pregnancy prevention survey. . . Results demonstrate that essential components of voluntary pregnancy prevention programs were not consistently followed, which resulted in fetal exposures.
Kovitwanichkanont T, Driscoll T (September 2018). "A comparative review of the isotretinoin pregnancy risk management programs across four continents". International Journal of Dermatology. 57 (9): 1035–1046. doi:10.1111/ijd.13950. PMID 29508918. S2CID 3726217.
Shah, Nidhi; Byrne, Morgan; Kirkorian, A. Yasmine (2021-09-01). "27483 Evaluating the economic burden of iPLEDGE on female patients". Journal of the American Academy of Dermatology. 85 (3): AB148. doi:10.1016/j.jaad.2021.06.606. ISSN 0190-9622.
Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3): e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.
Tirado Sánchez A, León Dorantes G (Nov–Dec 2005). "Erectile dysfunction during isotretinoin therapy". Actas Urologicas Espanolas. 29 (10): 974–6. doi:10.1016/s0210-4806(05)73379-9. PMID 16447596.

fda.gov

Research, Center for Drug Evaluation and (2018-11-03). "Drug Safety and Availability - Isotretinoin (marketed as Accutane) Capsule Information". FDA. Retrieved 2018-12-16.
Research, Center for Drug Evaluation and (2021-10-12). "iPLEDGE Risk Evaluation and Mitigation Strategy (REMS)". FDA.
"FDA targets illegal online pharmacies in globally coordinated action". Food and Drug Administration. Archived from the original on 2017-02-17. Retrieved 2019-12-16.
"RISK EVALUATION AND MITIGATION STRATEGY (REMS)" (PDF). www.fda.gov. 2012. Retrieved 2019-07-03.

harvard.edu

ui.adsabs.harvard.edu

Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3): e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

ipledgeprogram.com

"iPledge REMS - Public Home Page". www.ipledgeprogram.com.
"iPledge REMS - iPLEDGE Privacy Notice & Terms of Use". www.ipledgeprogram.com.
"iPledge REMS - Public Home Page". www.ipledgeprogram.com.

isciii.es

scielo.isciii.es

Tirado Sánchez A, León Dorantes G (Nov–Dec 2005). "Erectile dysfunction during isotretinoin therapy". Actas Urologicas Espanolas. 29 (10): 974–6. doi:10.1016/s0210-4806(05)73379-9. PMID 16447596.

jaad.org

Shah, Nidhi; Byrne, Morgan; Kirkorian, A. Yasmine (2021-09-01). "27483 Evaluating the economic burden of iPLEDGE on female patients". Journal of the American Academy of Dermatology. 85 (3): AB148. doi:10.1016/j.jaad.2021.06.606. ISSN 0190-9622.

jamanetwork.com

Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.

mdedge.com

"iPLEDGE vexes dermatologists treating transgender patients". www.mdedge.com. Retrieved 2021-03-20.

medscape.com

Darves, Bonnie (March 9, 2006). "Dermatologists Frustrated With Problematic iPledge Program". Medscape.
"Dermatologists Frustrated With Problematic iPledge Program". Medscape.

nih.gov

pubmed.ncbi.nlm.nih.gov

Layton A (May 2009). "The use of isotretinoin in acne". Dermato-Endocrinology. 1 (3): 162–9. doi:10.4161/derm.1.3.9364. PMC 2835909. PMID 20436884.
Layton AM, Knaggs H, Taylor J, Cunliffe WJ (September 1993). "Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment". The British Journal of Dermatology. 129 (3): 292–6. doi:10.1111/j.1365-2133.1993.tb11849.x. PMID 8286227. S2CID 22251719.
Thiboutot DM, Cockerell CJ (August 2006). "iPLEDGE: A Report from the Front Lines of Dermatologic Practice". The Virtual Mentor. 8 (8): 524–8. doi:10.1001/virtualmentor.2006.8.8.pfor1-0608. PMID 23234692.
Sladden MJ, Harman KE (September 2007). "What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?". Archives of Dermatology. 143 (9): 1187–8. doi:10.1001/archderm.143.9.1187. PMID 17875883.
Shin, Janet; Cheetham, T. Craig; Wong, Linda; Niu, Fang; Kass, Elizabeth; Yoshinaga, Monica A.; Sorel, Mike; McCombs, Jeffrey S.; Sidney, Stephen (December 2011). "The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system". Journal of the American Academy of Dermatology. 65 (6): 1117–1125. doi:10.1016/j.jaad.2010.09.017. PMID 21565419.
Prevost N, English JC (October 2013). "Isotretinoin: update on controversial issues". Journal of Pediatric and Adolescent Gynecology. 26 (5): 290–3. doi:10.1016/j.jpag.2013.05.007. PMID 24147278.
Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, Koren G, Lavigne SV, Martinez LP, Miller RK, Carey JC (November 2005). "A survey of pregnant women using isotretinoin". Birth Defects Research. Part A, Clinical and Molecular Teratology. 73 (11): 881–7. doi:10.1002/bdra.20197. PMID 16228976. Almost 1/4 of the women surveyed (24%; 8/34) did not recall having contraception counselling before starting their medications. Once therapy was initiated, 62% (21/34) recalled using a birth control method, but only 29% (6/21) recalled using 2 forms of birth control, as specified by the voluntary pregnancy prevention programs. Monthly pregnancy tests were not always conducted during treatment, as recalled by the surveyed women (56%; 19/34). As many as 24% (8/34) of the women surveyed recalled that they were not screened using 2 pregnancy tests before receiving a prescription, another recommendation of the programs. Only a small number of the women (30%; 6/20) in the United States recalled being enrolled in any manufacturers' voluntary pregnancy prevention survey. . . Results demonstrate that essential components of voluntary pregnancy prevention programs were not consistently followed, which resulted in fetal exposures.
Leyden JJ, Del Rosso JQ, Baum EW (February 2014). "The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions". The Journal of Clinical and Aesthetic Dermatology. 7 (2 Suppl): S3–S21. PMC 3970835. PMID 24688620.
Kovitwanichkanont T, Driscoll T (September 2018). "A comparative review of the isotretinoin pregnancy risk management programs across four continents". International Journal of Dermatology. 57 (9): 1035–1046. doi:10.1111/ijd.13950. PMID 29508918. S2CID 3726217.
Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3): e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.
Tirado Sánchez A, León Dorantes G (Nov–Dec 2005). "Erectile dysfunction during isotretinoin therapy". Actas Urologicas Espanolas. 29 (10): 974–6. doi:10.1016/s0210-4806(05)73379-9. PMID 16447596.

ncbi.nlm.nih.gov

Layton A (May 2009). "The use of isotretinoin in acne". Dermato-Endocrinology. 1 (3): 162–9. doi:10.4161/derm.1.3.9364. PMC 2835909. PMID 20436884.
Leyden JJ, Del Rosso JQ, Baum EW (February 2014). "The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions". The Journal of Clinical and Aesthetic Dermatology. 7 (2 Suppl): S3–S21. PMC 3970835. PMID 24688620.
Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3): e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.

researchgate.net

"Transgender Patients, Isotretinoin, and US Food and Drug Administration-Mandated Risk Evaluation and Mitigation Strategies: A Prescription for Inclusion". ResearchGate. Retrieved 2021-03-20.

semanticscholar.org

api.semanticscholar.org

Layton AM, Knaggs H, Taylor J, Cunliffe WJ (September 1993). "Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment". The British Journal of Dermatology. 129 (3): 292–6. doi:10.1111/j.1365-2133.1993.tb11849.x. PMID 8286227. S2CID 22251719.
Kovitwanichkanont T, Driscoll T (September 2018). "A comparative review of the isotretinoin pregnancy risk management programs across four continents". International Journal of Dermatology. 57 (9): 1035–1046. doi:10.1111/ijd.13950. PMID 29508918. S2CID 3726217.

the-dermatologist.com

"Isotretinoin Update | The Dermatologist". www.the-dermatologist.com.
Life After iPLEDGE, The Dermatologist, September 4, 2008.

web.archive.org

"FDA targets illegal online pharmacies in globally coordinated action". Food and Drug Administration. Archived from the original on 2017-02-17. Retrieved 2019-12-16.

worldcat.org

search.worldcat.org

Shah, Nidhi; Byrne, Morgan; Kirkorian, A. Yasmine (2021-09-01). "27483 Evaluating the economic burden of iPLEDGE on female patients". Journal of the American Academy of Dermatology. 85 (3): AB148. doi:10.1016/j.jaad.2021.06.606. ISSN 0190-9622.
Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3): e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.